hrp0086p2-p530 | Fat Metabolism and Obesity P2 | ESPE2016

Vascular Endothelial Growth Factor as The Predictor Microangiopathy in Obese and Diabetic Children

Ben-Skowronek Iwona , Kapczuk Iga , Stapor Natalia , Banecka Bozena

Background: Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Serum concentration of VEGF is high in bronchial asthma and diabetes mellitus. Overexpression of VEGF can cause vascular disease in the retina of the eye and other parts of the body.Objective and hypotheses: The...

hrp0094p2-273 | Growth hormone and IGFs | ESPE2021

The results of treatment with growth hormone in a patient with growth hormone deficiency and type 1 diabetes

Rakus-Kwiatosz Anna , Banecka Bozena , Ben-Skowronek Iwona ,

Introduction: Currently, the incidence of diabetes in children is increasing and may coexist with growth hormone deficiency. In diabetic patients, there are many mechanisms which disrupt the growth process and affect the GH/IGF-1 axis. However, with properly controlled diabetes, patients achieve normal height and should be diagnosed for causes of short stature other than diabetes. There are few reports on the safety and effects of the use of recombinant human ...

hrp0086p2-p269 | Diabetes P2 | ESPE2016

Which Group of Children Achieved the Best Results During Insulin Pump Therapy – Long-term Outcome in Children with Type 1 Diabetes?

Ben-Skowronek Iwona , Piekarski Robert , Wysocka Beata , Bury Anna , Banecka Bozena , Krzewska Aleksandra , Sieniawska Joanna , Kabat Magdalena , Rebowicz Katarzyna , Osiak Wiktoria , Szewczyk Leszek

Background: CSII has some potential advantages and disadvantages for young children. For many young patients, it is easier and more convenient to take multiple daily doses of insulin with CSII than with a syringe or insulin pen.Objective and hypotheses: The growing popularity of type 1 diabetes (DM1) treatment based on continuous subcutaneous insulin infusion (CSII) raises a question of the group of patients that benefit most from the treatment.<p cl...